Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kentucky
Clinical trial register · United States · industry-sponsored

Clinical Trials in Kentucky, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca42 Merck Sharp & Dohme LLC38 Eli Lilly and Company22 Janssen Research & Development, LLC20 AbbVie19
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Kentucky

771 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
NCT07459634Extensive-stage Small-cell Lung Cancer
DrugsLurbinectedin·Durvalumab
Jazz Pharmaceuticals
Phase 2
50
California, Florida, Georgia, Kentucky, South Carolina
2026-11-30
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
District of Columbia, Florida, Illinois, Kentucky
2026-10-19
Not yet open
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
NCT07845500Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
DrugsBerobenatide·Tirzepatide·Semaglutide
Pfizer
Phase 3
660
Alabama, Florida, Kentucky, Michigan, Missouri, Montana, North Carolina, Ohio
2026-10-01
Not yet open
Knee Cartilage Repair Registry
NCT07786207Knee Injuries, Joint Surface Knee Lesions
Smith & Nephew, Inc.
Observational
1,000
Colorado, District of Columbia, Indiana, Kentucky, Oklahoma, Pennsylvania
2026-09-30
Recruiting
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
NCT07828860Hidradenitis Suppurativa (HS)
DrugSoquelitinib
Corvus Pharmaceuticals, Inc.
Phase 1
25
Indiana, Kentucky, Massachusetts, New York, North Dakota, Ohio, Pennsylvania, Tennessee
2026-09-17
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-09-11
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig
Bristol-Myers Squibb
Phase 2
160
District of Columbia, Georgia, Kentucky, Maryland, Mississippi, Nebraska, New York, Ohio
2026-09-10
Recruiting
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
NCT07645248Asthma
GlaxoSmithKline
Phase 3
110
Florida, Kentucky, Missouri, Nevada, Oregon, South Carolina, Texas
2026-09-01
Not yet open
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
NCT07766005Hidradenitis Suppurativa (HS)
DrugsSPY072·Bimekizumab
Spyre Therapeutics, Inc.
Phase 2
150
California, Indiana, Kentucky, Louisiana, Massachusetts, New York, South Carolina, Texas
2026-09
Recruiting
A Study of COVID-19 Vaccine(s) in Children and Adults
NCT07798648COVID-19 Vaccines
DrugComirnaty
BioNTech SE
Phase 3
700
Florida, Georgia, Hawaii, Kentucky, Ohio, Pennsylvania, Texas, Utah
2026-08-31
Recruiting
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
NCT07816185Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 3
376
Florida, Kentucky, Oregon
2026-08-31
Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
NCT07527299Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
1,070
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Kentucky, New York
2026-08-26
Recruiting
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
NCT07795814Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics, Inc.
Phase 2
90
Alabama, California, Illinois, Indiana, Kentucky, Louisiana, Maryland, Michigan
2026-08-25
Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841Overweight, Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
450
Alabama, California, Florida, Hawaii, Kentucky, Missouri, Nevada, Oregon
2026-08-12
Not yet open
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
NCT07742644Measles, Mumps, Rubella, Varicella (Chickenpox)
GlaxoSmithKline
Phase 3
1,860
Arkansas, California, Florida, Idaho, Illinois, Kentucky, Louisiana, Missouri
2026-08-11
Not yet open
Safety and Efficacy of a 2,910 nm Fractional Ablative Fiber Laser (UltraClear®) for Improvements of Skin Laxity and Lifting of the Lower Face, Submental, and Neck Treatment Areas
NCT07759817Skin Laxity (Submental and Neck), Skin Lifting and Tightening
FA Corporation
Not applicable
50
Kentucky, Texas
2026-08-07
Recruiting
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
NCT07752979Obesity, Overweight
DrugABBV-295
AbbVie
Phase 2
360
Alabama, Arizona, California, Florida, Idaho, Illinois, Kentucky, Missouri
2026-08-04
Recruiting
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504Overweight, Obesity
DrugCagrilintide
Novo Nordisk A/S
Phase 3
285
Georgia, Hawaii, Illinois, Indiana, Kentucky, North Carolina, South Carolina, Virginia
2026-08-04
Recruiting
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
DrugApraglutide
VectivBio AG
Phase 3
124
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Michigan, New York
2026-08
Recruiting
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
NCT07575308Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
DrugALN-6400
Alnylam Pharmaceuticals
Phase 2
24
California, Florida, Kentucky, Pennsylvania
2026-07-30
Recruiting
Modified P200TE Data Collection
NCT07796230Retina Disease
Optos, PLC
Observational
50
Kentucky
2026-07-29
Recruiting
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
NCT07685808Overweight or Obesity
DrugOlatorepatide
Regeneron Pharmaceuticals
Phase 2
360
Alabama, California, Florida, Illinois, Kansas, Kentucky, New York, South Carolina
2026-07-28
Recruiting
Mako-MORE Registry
NCT07647354Arthropathy of Knee, Arthropathy of Hip
Stryker Orthopaedics
Observational
950
Florida, Kentucky, New York, Ohio, Rhode Island
2026-07-13
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
NCT07717879ADHD
DrugsSolriamfetol A·Solriamfetol B
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-07-06
Recruiting
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
NCT07324031Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
AtaCor Medical, Inc.
Not applicable
280
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kentucky
2026-07-02
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Small Cell Lung Cancer
DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan
AbbVie
Phase 3
531
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-07-02
Recruiting
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT07453888Non-Arteritic Anterior Ischemic Optic Neuropathy
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
272
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2026-07-01
Active, closed
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122Obesity, Overweight
DrugBI 3034701
Boehringer Ingelheim
Phase 2
344
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Not yet open
Evaluation of the Safety and Effectiveness of the CORUS™ Posterior Cervical Stabilization System 3D (PCSS 3D) for the Treatment of 2-level Cervical Degenerative Disease
NCT07721493Degenerative Disc Disease(DDD)
Providence Medical Technology, Inc.
Not applicable
225
Kentucky
2026-06-30
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371Moderate-to-Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 3
510
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-06-29
Recruiting
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
NCT07717892ADHD
DrugsSolriamfetol A·Solriamfetol B
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-06-25
Recruiting
A Study of MZE782 in Adults With PKU
NCT07694440Phenylketonuria (PKU)
Maze Therapeutics
Phase 2
38
California, Indiana, Kentucky, Pennsylvania, Tennessee
2026-06-23
Recruiting
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471Follicular Lymphoma
DrugsRituximab Biosimilar·MK-1045·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 2/3
960
California, Kentucky, New Jersey, North Carolina, Tennessee
2026-06-22
Recruiting
A Study of ARC-02 in B-cell NHL
NCT07691606B-cell Non Hodgkin Lymphoma
DrugRituximab
Taiho Oncology, Inc.
Phase 1
140
California, Kentucky, New York, North Carolina, Virginia, Washington, Wisconsin
2026-06-22
Recruiting
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
NCT07644052Cannabis Withdrawal
DrugNabilone
PleoPharma, Inc.
Phase 3
420
Arkansas, Connecticut, Florida, Georgia, Kentucky, Maryland, Nevada, New Jersey
2026-06-17
Recruiting
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
NCT07477704Hypercholesterolemia
DrugsPraluent·Alirocumab
Regeneron Pharmaceuticals
Phase 2
420
Alabama, California, Florida, Georgia, Hawaii, Kentucky, Louisiana, Montana
2026-06-17
Recruiting
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
NCT07564401Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals
Phase 1/2
80
Kentucky, Texas, Washington
2026-06-16
Recruiting
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
NCT07660198Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 3
1,200
Alabama, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Massachusetts
2026-06-15
Recruiting
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT07647328ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Ribociclib
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Active, closed
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
NCT07656727Obesity and Cardiovascular Risk
DrugBGE-102
BioAge Labs, Inc.
Phase 2
160
Arizona, Arkansas, Florida, Kentucky, Maryland, Missouri, Nevada, New York
2026-06-11
Recruiting
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
NCT07595549Obesity, Overweight and/or Obesity, Overweight
DrugBerobenatide
Pfizer
Phase 3
954
California, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Nebraska
2026-06-10
Recruiting
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
NCT07682896Graves' Disease
Yarrow Bioscience, Inc.
Phase 2
232
Arizona, California, Florida, Georgia, Kentucky, Michigan, Nebraska, New York
2026-06-10
Active, closed
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021Obesity
DrugsNNC0662-0419·Semaglutide
Novo Nordisk A/S
Phase 2
233
Alabama, California, Florida, Illinois, Indiana, Kentucky, Maryland, Missouri
2026-06-09
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
DrugsArsenic Trioxide·ATRA
Quetzal Therapeutics
Phase 3
150
Alabama, California, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2026-06-08
Recruiting
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
NCT07489885Psoriasis
DrugD-2570
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Recruiting
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
NCT07661329Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
YS Life Science Co., Ltd.
Phase 3
600
California, Florida, Georgia, Kentucky, Missouri, Texas
2026-06-02
Recruiting
Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
NCT07290140Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Airiver Medical, Inc.
Not applicable
300
Alabama, California, Colorado, Iowa, Kentucky, Pennsylvania, South Carolina, Texas
2026-06-01
Not yet open
Mitral Valve Repair With the Chord-X System: A Long Term Evaluation
NCT07413926Mitral Regurgitation (MR)
Artivion Inc.
Observational
110
Kentucky
2026-06
Recruiting
A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
NCT07570758Obesity & Overweight
ERX Pharmaceuticals
Phase 2
80
Kentucky, North Carolina, South Carolina
2026-05-28
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-22
Recruiting
Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency
NCT07636590Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.
Observational
500
Indiana, Kansas, Kentucky, Minnesota, Oregon, Tennessee, Texas
2026-05-22
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480Myelodysplastic Syndrome, Anemia
DrugsElritercept·Epoetin Alfa
Takeda
Phase 3
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana
2026-05-21
Recruiting
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608Overweight, Obesity
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
400
Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Kentucky
2026-05-15
Recruiting
AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE
NCT07277946Hernia
Tissium
Not applicable
240
California, Florida, Illinois, Kentucky, Michigan, Nebraska, North Carolina, Ohio
2026-05-14
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098Breast Neoplasms
DrugsImlunestrant·Goserelin·Tamoxifen
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
NCT07265674Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
J-Pharma Co., Ltd.
Phase 3
480
California, Florida, Illinois, Kentucky, Louisiana, Michigan, Minnesota, Nevada
2026-05-11
Recruiting
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
NCT07535034Gout
DrugDotinurad
Crystalys Therapeutics
Phase 2
90
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-05-08
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
DrugSurovatamig
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
NCT07573462Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 3
2,400
Florida, Georgia, Idaho, Illinois, Kentucky, Louisiana, Massachusetts, New York
2026-05-04
Recruiting
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
NCT07610395Rhinovirus Infection
Altesa Biosciences, Inc.
Phase 2
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-05-01
By invitation
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
NCT07637162Fibromyalgia
DrugEsreboxetine
Axsome Therapeutics, Inc.
Phase 3
300
Arkansas, California, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana
2026-04-29
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
DrugBrenipatide
Eli Lilly and Company
Phase 2
342
Arizona, California, Florida, Illinois, Indiana, Kentucky, New York, Ohio
2026-04-29
Recruiting
Phase 2 Study to Assess the Safety and Efficacy of ANG003
NCT07450547Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Anagram Therapeutics, Inc.
Phase 2
113
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Maine
2026-04-24
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332Pulmonary Arterial Hypertension
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
Recruiting
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307Obesity, Overweight, Osteoarthritis, Knee
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Missouri, New York
2026-04-20
Recruiting
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06769698Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York
2026-04-14
Recruiting
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
NCT07525375Asthma
AstraZeneca
Phase 2
69
California, Florida, Kentucky, Louisiana, Massachusetts, Missouri, Ohio, Oklahoma
2026-04-14
Recruiting
Effectiveness and Safety of OviTex® PRS in Breast Reconstruction
NCT07135596Breast Reconstruction
Tela Bio Inc
Not applicable
235
Florida, Kentucky, North Carolina
2026-04-10
Recruiting
Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
NCT07543757Prostate Cancer Detection
Sequenom, Inc.
Observational
500
California, Idaho, Kentucky, Maryland, New York, South Carolina
2026-04-03
Not yet open
Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)
NCT07513506Growth
Mead Johnson Nutrition
Not applicable
214
Alabama, Arkansas, Florida, Illinois, Kentucky, North Carolina, Tennessee, Texas
2026-04-03
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159Asthma
Sanofi
Observational
2,500
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Montana
2026-04-01
Recruiting
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
NCT07524946Acne Vulgaris
Bausch Health Americas, Inc.
Phase 4
100
Arkansas, California, Florida, Kentucky, Michigan, Nevada, New York, North Carolina
2026-04-01
Recruiting
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
DrugsTam-Peli·Atezolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
District of Columbia, Florida, Kentucky, Texas, Virginia
2026-03-31
Recruiting
Testing Conversational Agents as a Digital Companion
NCT07533331Autism
Friendi.fi Corporation
Not applicable
38
Indiana, Kentucky
2026-03-21
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
California, Colorado, Florida, Kentucky, Michigan, Minnesota, Missouri, New York
2026-03-16
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Alabama, Arizona, California, Connecticut, Georgia, Hawaii, Illinois, Kentucky
2026-03-16
Recruiting
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
NCT07185971Homonymous Hemianopsia, Homonymous Quadrantanopia
NeuroAEye LLC
Not applicable
20
Iowa, Kentucky
2026-03-16
Recruiting
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
NCT07339111Knee Cartilage Defects
Medipost, Inc.
Phase 3
300
Alabama, Arizona, California, Colorado, Illinois, Kentucky, Louisiana, Michigan
2026-03-11
Recruiting
Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar
NCT07337590Colorectal Cancer
Exero Medical Ltd.
Not applicable
80
Kentucky, Maryland, Nebraska, New York, Pennsylvania
2026-03-10
Active, closed
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
NCT07458269Obesity
DrugRibupatide
Kailera
Phase 2
264
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-03-04
By invitation
Persona SoluTion PPS Femur PMCF
NCT07286513Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis), Polyarthritis
Zimmer Biomet
Observational
200
Colorado, Kentucky, Maryland
2026-02-26
Recruiting
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
NCT07432958Parkinson Disease
Appello Pharmaceuticals, Inc.
Phase 2
150
Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky
2026-02-25
Recruiting
A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425Solid Tumours, Melanoma
Boehringer Ingelheim
Phase 1
69
Kentucky, Tennessee, Texas, Virginia
2026-02-24
Recruiting
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
240
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts
2026-02-23
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsSetidegrasib·Levofolinate·Liposomal Irinotecan·Fluorouracil
Astellas Pharma Global Development, Inc.
Phase 3
614
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Indiana, Kentucky
2026-02-17
Recruiting
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283Opioid Use Disorder
DrugsBuprenorphine·Brenipatide
Eli Lilly and Company
Phase 2
465
Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maryland
2026-02-13
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dovato·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Active, closed
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Recruiting
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT07280013Multiple Myeloma (MM)
DrugsCemsidomide·Elranatamab
C4 Therapeutics, Inc.
Phase 1
60
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-02-06
Recruiting
A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
NCT07118501Post Traumatic Arthritis, Osteoarthritis, Total Ankle Replacement, Total Ankle Prosthesis
Stryker Trauma and Extremities
Observational
200
Illinois, Indiana, Kentucky, Oregon, South Carolina
2026-02-06
Recruiting
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
NCT07102160Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
Argon Medical Devices
Observational
185
Florida, Kentucky, Texas
2026-02-04
Recruiting
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07213973Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 2
40
Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-02-02
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
DrugsGocatamig·Ifinatamab Deruxtecan·Etoposide·Atezolizumab
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Recruiting
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
NCT07323654Eosinophilic Asthma
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
264
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas, Kentucky
2026-01-28
Active, closed
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Hawaii, Kentucky, Massachusetts, Michigan, New York
2026-01-24
Recruiting
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
NCT07348692Pneumococcal Immunization, Healthy Volunteers
DrugsPCV21 vaccine·Prevnar 20
Sanofi
Phase 3
2,195
Arkansas, California, Florida, Kentucky, Michigan, New York, South Carolina, Texas
2026-01-20
Recruiting
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
240
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-01-15
Recruiting
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
NCT07300267Pneumococcal Infection
DrugPrevnar 20
Merck Sharp & Dohme LLC
Phase 1
210
California, Florida, Kansas, Kentucky, Maryland, Missouri, New York, South Carolina
2026-01-13
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
California, Florida, Iowa, Kentucky, Pennsylvania, Virginia
2026-01-12
Active, closed
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
NCT07365826Pneumococcal Vaccines
Drug31-valent pneumococcal conjugate vaccine
Vaxcyte, Inc.
Phase 3
1,390
Arizona, Colorado, Florida, Indiana, Kansas, Kentucky, Michigan, Nebraska
2026-01-12
Recruiting
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
NCT07301255Asthma
DrugENV-294
Enveda Therapeutics
Phase 2
50
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2026-01-09
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975Hidradenitis Suppurativa (HS)
Navigator Medicines, Inc.
Phase 2
150
Arizona, Florida, Kentucky, Massachusetts, Mississippi, New Hampshire, New York
2026-01-05
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569Hidradenitis Suppurativa
Sanofi
Phase 2
144
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-12-29
Active, closed
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660Atopic Dermatitis
DrugGalvokimig
UCB Biopharma SRL
Phase 2
165
California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska
2025-12-29
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-12-29
Recruiting
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
NCT07254806Degenerative Disc Disease
DiscGenics, Inc.
Phase 3
162
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Indiana, Kentucky
2025-12-23
Recruiting
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07298395Atopic Dermatitis (AD)
DrugENV-294
Enveda Therapeutics
Phase 2
105
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-12-22
Active, closed
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
NCT06323447Diffuse Large B Cell Lymphoma, Multiple Myeloma
Leuko Labs, Inc.
Observational
210
Hawaii, Kentucky, Massachusetts, New Jersey, Texas
2025-12-15
Active, closed
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
DrugsEzetimibe FDC·Obicetrapib
NewAmsterdam Pharma
Phase 3
300
Arizona, California, Florida, Idaho, Illinois, Kentucky, Maine, Maryland
2025-12-11
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2025-12-09
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Active, closed
EMVITAL + EMFACE Combination Therapy for Temporomandibular Joint (TMJ) Pain Relief
NCT07661121Temporomandibular Disorder (TMD), Temporomandibular Joint Pain, Facial Pain, Neck Pain
BTL Industries Ltd.
Not applicable
48
Florida, Kentucky, Texas
2025-12-08
Active, closed
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
NCT07310901Obese But Otherwise Healthy Participants
Corbus Pharmaceuticals Inc.
Phase 1
252
Alabama, Arizona, California, Florida, Kentucky, Nevada, New York, North Carolina
2025-12-04
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
RayzeBio, Inc.
Phase 1
104
Arizona, Florida, Iowa, Kentucky, Minnesota, Missouri, Ohio, Oregon
2025-12-03
Recruiting
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638Focal Segmental Glomerulosclerosis
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-12-03
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Maryland
2025-11-30
Recruiting
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
By invitation
Safety and Efficacy of Ellacor® Micro-coring® Following Best Practices on Technique and Post-Procedural Care
NCT07260578Best Practices, Ellacor, Micro-coring Post Care, Ellacor Post Care
Cytrellis Biosystems, Inc.
Not applicable
24
Florida, Kentucky
2025-11-26
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab
AbbVie
Phase 2
180
Connecticut, Florida, Indiana, Kentucky, Massachusetts, Michigan, Missouri, Ohio
2025-11-25
Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT06890338Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
DrugsMIRV·Mirvetuximab Soravtansine·Bevacizumab·Carboplatin
AbbVie
Phase 2
140
Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana
2025-11-21
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Arizona, California, Connecticut, Florida, Georgia, Iowa, Kentucky, Louisiana
2025-11-19
Active, closed
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
250
California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2025-11-17
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
DrugsFludarabine·Cyclophosphamide
Allogene Therapeutics
Phase 1
66
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky
2025-11-13
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845Ovarian Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab·Carboplatin
AbbVie
Phase 2
400
California, Florida, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Montana
2025-11-13
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 2
160
Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky
2025-11-12
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Michigan
2025-11-07
Recruiting
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 1
24
Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-11-03
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan
2025-11-03
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin
BioNTech SE
Phase 3
558
Arkansas, California, Florida, Illinois, Kentucky, Maine, Maryland, Massachusetts
2025-10-30
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
AtriCure, Inc.
Not applicable
960
Arkansas, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-10-24
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Colorado, Florida, Illinois, Kentucky, Massachusetts, Nevada
2025-10-22
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
California, Kentucky, Michigan, New Jersey, New York, Texas
2025-10-21
Active, closed
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
NCT07074977Chronic Pruritus of Unknown Origin
DrugNemolizumab
Galderma R&D
Phase 2
50
Alabama, Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-10-20
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
1,196
California, Colorado, Florida, Georgia, Idaho, Kentucky, Louisiana, Maine
2025-10-20
Recruiting
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
NCT07147296Spinal Cord Injuries, Blood Pressure Disorders
ONWARD Medical, Inc.
Not applicable
60
Arkansas, Colorado, Florida, Georgia, Kentucky, Maryland, Massachusetts, Minnesota
2025-10-17
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
470
Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Maryland, Massachusetts
2025-09-30
Recruiting
IVUS CHIP UPP Registry
NCT06625801Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
ECRI bv
Observational
1,010
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota
2025-09-30
Recruiting
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
NCT07195656Overactive Bladder (OAB)
FemPulse Corporation
Not applicable
151
California, Florida, Illinois, Kentucky, Maryland, Minnesota, Nebraska, North Carolina
2025-09-30
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312Acute Myeloid Leukemia (AML)
DrugsZiftomenib·Venclyxto·Ara-C·Daunorubicin
Kura Oncology, Inc.
Phase 3
1,300
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, Massachusetts
2025-09-26
Recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758Extensive Stage Small Cell Lung Cancer
DrugsEtakafusp alfa·Tarlatamab
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161Hypertension, Uncontrolled Hypertension
DrugIloperidone
Vanda Pharmaceuticals
Phase 2
240
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri
2025-09-15
Recruiting
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
NCT06726161Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.
Phase 1/2
590
Alabama, Arizona, California, Florida, Kentucky, Maryland, Minnesota, Missouri
2025-09-05
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707Obesity
MBX Biosciences
Phase 1
124
Florida, Kentucky, Missouri, Tennessee
2025-09-03
Recruiting
Post-Approval Study of the Neuspera Sacral Neuromodulation System
NCT07144813Urinary Urgency Incontinence
Neuspera Medical, Inc.
Not applicable
116
California, Florida, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota
2025-09-03
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Texas, Virginia
2025-08-26
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Alabama, California, Florida, Illinois, Kentucky, Maryland, Michigan, Minnesota
2025-08-26
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Alabama, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana, Maryland
2025-08-22
Recruiting
FIBERGRAFT Aeridyan Posterolateral Fusion Study
NCT07059065Degenerative Spine Disease
DePuy Synthes Products, Inc.
Not applicable
316
California, Illinois, Kentucky, Massachusetts, Pennsylvania
2025-08-15
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
150
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-08-14
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-08-11
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849Sickle Cell Disease Vaso-occlusive Crisis
DrugIVIG
CSL Behring
Phase 2
70
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, Missouri
2025-08-07
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
DrugsTzield·Teplizumab
Sanofi
Phase 3
723
Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho, Kentucky
2025-08-06
Active, closed
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
NCT07092865Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 2
168
Kentucky, Missouri, Nebraska, New York, Pennsylvania, Texas
2025-08-06
Recruiting
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
NCT07096193Chronic Hepatitis Delta
Gilead Sciences
Phase 1/2
200
California, Kentucky, Maryland, New York
2025-07-31
Recruiting
WRAP North America
NCT06807099Venous Stenosis, Venous Occlusion
Merit Medical Systems, Inc.
Observational
250
Alabama, Arizona, California, Florida, Kentucky, Rhode Island, South Carolina, Tennessee
2025-07-31
Recruiting
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
NCT06850805Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
Phase 3
84
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kentucky, Maryland
2025-07-28
Recruiting
ELEVATE High-Risk PCI Pivotal Study
NCT07001332High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.
Not applicable
290
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-07-25
Recruiting
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
NCT07070115Hiatal Hernia
Tela Bio Inc
Not applicable
173
Alabama, Colorado, Kentucky, North Carolina, Texas
2025-07-25
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
California, Florida, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Missouri
2025-07-24
Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
NCT06911632Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Tempus AI
Not applicable
900
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky
2025-07-23
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Alabama, Arizona, California, District of Columbia, Florida, Kentucky, Louisiana, Massachusetts
2025-07-21
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Colorado, Delaware, Florida, Kentucky, New Jersey
2025-07-21
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Arizona, Florida, Illinois, Kentucky, Maryland, Missouri, New Jersey
2025-07-21
Active, closed
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
80
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2025-07-18
Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515Acute Decompensated Heart Failure
DrugFurosemide
Reprieve Cardiovascular, Inc
Phase 3
400
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Minnesota
2025-07-14
Recruiting
ELEVATE-HFpEF Clinical Study
NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
700
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2025-07-09
Recruiting
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
NCT07028749Hypertriglyceridemia
DrugMAR001
Marea Therapeutics
Phase 2
316
Alabama, Arkansas, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-06-30
Recruiting
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800Moderate Aortic Valve Stenosis
Kardigan, Inc.
Phase 2/3
1,276
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-27
Recruiting
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
NCT06998524Von Willebrand Disease, Type 3
DrugEmicizumab
Hoffmann-La Roche
Phase 3
75
California, Florida, Kentucky, Minnesota, Missouri, Virginia
2025-06-27
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Alabama, Arizona, California, Colorado, Florida, Kentucky, Michigan, Minnesota
2025-06-27
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2025-06-27
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
835
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-27
Recruiting
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
NCT06935591Atrial Fibrillation (AF)
Vektor Medical
Not applicable
423
Arkansas, Florida, Georgia, Indiana, Kentucky, New York, Ohio, Pennsylvania
2025-06-27
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
290
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
Recruiting
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
NCT06464926Nausea, Vomiting
Enterra Medical, Inc.
Not applicable
148
Arizona, California, Florida, Illinois, Indiana, Kentucky, New Jersey, Ohio
2025-06-23
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
210
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Missouri
2025-06-19
Active, closed
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
NCT06699836Metastatic Colorectal Cancer (mCRC)
DrugsLeronlimab·Keytruda·Pembrolizumab
CytoDyn, Inc.
Phase 2
66
California, District of Columbia, Kentucky, Nebraska, Pennsylvania, Washington
2025-06-16
Active, closed
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
NCT07009860Alcohol-associated Liver Disease
DrugPemvidutide
Altimmune, Inc.
Phase 2
121
Arizona, Arkansas, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-06-16
Active, closed
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792Atopic Dermatitis
DrugLebrikizumab
Eli Lilly and Company
Phase 4
233
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-16
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
630
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Louisiana
2025-06-11
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana
2025-05-30
Active, closed
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706Atopic Dermatitis, Atopic, Dermatitis, AD
Aclaris Therapeutics, Inc.
Phase 2
110
Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana, Kentucky
2025-05-30
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel
Merck Sharp & Dohme LLC
Phase 2
144
Kentucky, Maryland, Texas, Virginia
2025-05-28
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
DrugsMIRV·Mirvetuximab Soravtansine
AbbVie
Phase 2
110
Florida, Kentucky, Massachusetts, Michigan, Pennsylvania, Texas
2025-05-28
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Alabama, Arkansas, California, Florida, Idaho, Illinois, Indiana, Kentucky
2025-05-28
Recruiting
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
NCT06787612Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsREGN10597·Ubamatamab·Sarilumab·Fianlimab
Regeneron Pharmaceuticals
Phase 2
297
Alabama, California, Florida, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
California, Colorado, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland
2025-05-27
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2025-05-19
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Active, closed
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610Hidradenitis Suppurativa (HS)
Zura Bio Inc
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Massachusetts
2025-05-16
Recruiting
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
350
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, New York
2025-05-14
Active, closed
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852Head and Neck Squamous Cell Carcinoma
DrugsBI 770371·Cetuximab·Pembrolizumab
Boehringer Ingelheim
Phase 1
91
Kentucky, Minnesota, Ohio
2025-05-14
Recruiting
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
NCT06780085Carcinoma, Non-Small-Cell Lung
DrugsR-DXd·Ifinatamab Deruxtecan
Merck Sharp & Dohme LLC
Phase 2
96
Kentucky, Maryland, Pennsylvania
2025-05-13
Active, closed
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
NCT06865079Osteoarthritis (OA) of the Knee
OrthoTrophix, Inc
Phase 2
270
Arizona, California, Florida, Georgia, Kansas, Kentucky, Louisiana, Minnesota
2025-05-09
Recruiting
EXoPERT EMERALD Clinical Study
NCT07186296Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
EXoPERT
Observational
1,400
California, Hawaii, Kentucky, Maryland, New York
2025-05-09
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
NCT06944925Chronic Obstructive Pulmonary Disease
DrugBBT002
Bambusa Therapeutics
Phase 1
286
Kentucky, New York
2025-05-08
Recruiting
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT06952660Cervical Cancer
DrugTivdak
Pfizer
Phase 4
100
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2025-05-07
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Missouri, Nevada
2025-05-06
Active, closed
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT06799247Myasthaenia Gravis
Cartesian Therapeutics
Phase 3
128
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2025-05-06
Recruiting
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962Crohns Disease
DrugsTRX103·Cyclophosphamide
Tr1X, Inc.
Phase 1/2
39
Arizona, California, Florida, Illinois, Iowa, Kentucky, Michigan, Minnesota
2025-05-05
Recruiting
Motiva Implants® Post-Approval Study
NCT06938399Breast Implant
Motiva USA LLC
Not applicable
2,400
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Louisiana, Maryland
2025-05-01
Recruiting
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
NCT06746883Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Innoviva Specialty Therapeutics
Observational
100
California, Florida, Kansas, Kentucky, Louisiana, New York, Ohio, Pennsylvania
2025-04-28
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, Ohio, Pennsylvania
2025-04-28
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky, Nebraska
2025-04-16
Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447Ovarian Cancer Recurrent
DrugsMK-2010·R-DXd·Zirabev·Mvasi
Merck Sharp & Dohme LLC
Phase 1/2
605
Connecticut, Kentucky, Louisiana, Massachusetts, New York, Oklahoma, Texas, Utah
2025-04-15
Recruiting
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
NCT06893588Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Vesalio
Observational
200
California, Connecticut, Florida, Georgia, Illinois, Iowa, Kentucky, Maine
2025-04-14
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
DrugClemizole HCl
Epygenix
Phase 3
260
Arkansas, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Nebraska
2025-04-09
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-04-09
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
California, Florida, Illinois, Kentucky, New Jersey, Ohio, Oregon, Texas
2025-04-08
Recruiting
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
NCT06708897CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
Lomond Therapeutics Holdings, Inc.
Phase 1
84
Kentucky, North Carolina, Ohio, Texas
2025-04-08
Active, closed
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 3
43
California, District of Columbia, Florida, Kentucky, Michigan, North Carolina, Ohio, Texas
2025-04-07
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maine
2025-04-04
Recruiting
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
NCT06664775Hemorrhage
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Recruiting
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
NCT06592638Small Cell Lung Cancer
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
30
California, Florida, Kentucky, Ohio, Texas
2025-03-31
Recruiting
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450Advanced Solid Tumors Cancer, MSI-H Cancer
Nimbus Wadjet, Inc.
Phase 1/2
134
California, Illinois, Kentucky, New York, North Carolina, Ohio, Rhode Island, South Carolina
2025-03-31
Recruiting
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
NCT06731907Non-small Cell Lung Cancer
DrugsPatritumab deruxtecan·Abraxane·Paraplatin·Taxol
Merck Sharp & Dohme LLC
Phase 2
90
Kentucky, Maryland, North Dakota, Pennsylvania, South Dakota
2025-03-30
Recruiting
MagDI U.S. Registry
NCT06928545Anastomosis, Surgical, Internal Hernia, Bowel Obstruction
GT Metabolic Solutions, Inc.
Observational
106
California, Florida, Kentucky, Louisiana, North Carolina, Washington
2025-03-28
Recruiting
A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects
NCT06843577Elevated Blood Pressure, Hypertension
Zona Health, Inc
Not applicable
160
California, Florida, Illinois, Kentucky, Pennsylvania, Tennessee, Texas
2025-03-27
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
DrugTozorakimab
AstraZeneca
Phase 2
540
California, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky
2025-03-26
Recruiting
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785Advanced Solid Tumor
OncoC4, Inc.
Phase 1/2
387
Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan
2025-03-26
Recruiting
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
NCT06843317RSV Infection
DrugArexvy
Clover Biopharmaceuticals USA, LLC
Phase 1
160
Arizona, Florida, Kentucky, Missouri, Tennessee
2025-03-21
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Kentucky, New Mexico, Texas
2025-03-21
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942Psoriasis, Overweight or Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Active, closed
Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
NCT06495424Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
DrugCapsaicin
Averitas Pharma, Inc.
Observational
144
Delaware, Georgia, Kentucky, New Jersey, Ohio, Pennsylvania
2025-03-14
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-03-10
Active, closed
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802Encephalitis
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Active, closed
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268Obesity
DrugRetatrutide
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
DrugsGlofitamab·Obinutuzumab·Oxaliplatin·Gemcitabine
Hoffmann-La Roche
Phase 2
130
Alaska, California, Colorado, Florida, Idaho, Illinois, Iowa, Kentucky
2025-03-05
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
NCT06841055Non-small Cell Lung Cancer
DrugsPumitamig·Docetaxel
BioNTech SE
Phase 2
60
Alabama, Florida, Kentucky, New York, Texas
2025-03-03
Active, closed
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
NCT06838000Pneumococcal Infections
DrugsCapvaxive·Prevnar 20
Sanofi Pasteur, a Sanofi Company
Phase 3
1,268
California, Florida, Georgia, Iowa, Kentucky, Mississippi, Nebraska, New York
2025-02-28
Active, closed
A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.
NCT06922955Nasal Airway Obstruction
Aerin Medical
Observational
400
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Michigan
2025-02-28
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
Clasp Therapeutics, Inc.
Phase 1
90
Arizona, California, Florida, Illinois, Kentucky, Maryland, New Jersey, New York
2025-02-28
Active, closed
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824181Pneumococcal Immunization
DrugsHavrix·Vaqta·M-M-R II vaccine·Prevnar 20 vaccine
Sanofi
Phase 3
580
California, Florida, Iowa, Kentucky, Louisiana, New York, Pennsylvania, South Carolina
2025-02-27
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
171
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-02-27
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
NCT06778447Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
VIVEX Biologics, Inc.
Not applicable
325
California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana
2025-02-17
Active, closed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Hawaii, Kentucky, Missouri, South Carolina, Tennessee, Texas
2025-02-10
Recruiting
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
NCT06616025Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
Neuraptive Therapeutics Inc.
Phase 3
98
California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-02-10
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Alabama, California, Florida, Illinois, Kentucky, Louisiana, Maryland, Ohio
2025-02-06
Recruiting
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629Proteinuric Kidney Disease
Maze Therapeutics
Phase 2
74
Alabama, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2025-02-05
Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Glioblastoma
DrugsTemozolomide·Keytruda·Pembrolizumab
NovoCure GmbH
Phase 3
741
Arizona, California, District of Columbia, Florida, Illinois, Kentucky, Maryland, Massachusetts
2025-02-03
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin
BioNTech SE
Phase 3
621
Arizona, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana
2025-02-03
Recruiting
PT150 Drug for Use in Alcohol Use Disorder
NCT06712602Alcohol Use Disorder
DrugAlcohol
Pop Test Oncology LLC
Phase 1
34
Kentucky
2025-02-01
Active, closed
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06769048Geographic Atrophy
Boehringer Ingelheim
Phase 2
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-31
Recruiting
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185Advanced Solid Tumor
BioNTech SE
Phase 1/2
248
Kentucky, Michigan, North Carolina, Rhode Island, South Carolina, Texas
2025-01-13
Active, closed
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016Female Contraception
Mylan Pharmaceuticals Inc
Phase 3
1,630
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky
2025-01-13
Active, closed
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)
NCT06852768oGHVD
Regenerative Ocular Immunobiologics LLC
Phase 1/2
15
California, Florida, Kentucky, Massachusetts
2025-01-10
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky
2025-01-08
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer
NextCure, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Active, closed
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06722157Macular Degeneration, Age-related, Geographic Atrophy
DrugsSyfovre·Pegcetacoplan
Boehringer Ingelheim
Phase 2
202
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-06
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugPirtobrutinib
Loxo Oncology, Inc.
Phase 2
249
Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky, Maryland
2025-01-03
Recruiting
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410Cutaneous Squamous Cell Carcinoma (CSCC)
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 3
369
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-01-02
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
DrugsVedolizumab·Upadacitinib
Takeda
Phase 3
396
California, Colorado, Florida, Indiana, Kentucky, New York, South Carolina, South Dakota
2025-01-02
Active, closed
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
35
Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kentucky
2024-12-30
Recruiting
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457Staphylococcus Aureus
DrugAZD7760
AstraZeneca
Phase 1/2
231
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2024-12-30
Recruiting
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
NCT06798896Focal Onset Seizures
DrugSPN-817
Supernus Pharmaceuticals, Inc.
Phase 2
216
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Kentucky, Louisiana
2024-12-30
Recruiting
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212Recurrent Head and Neck Squamous Cell Carcinoma
DrugsAdrucil·Docetaxel·Keytruda·Paclitaxel
Rakuten Medical, Inc.
Phase 3
412
California, Florida, Kentucky, Pennsylvania, Rhode Island, South Dakota, Texas
2024-12-24
Active, closed
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985Hepatocellular Carcinoma
DrugsToripalimab·Bevacizumab
Coherus Oncology, Inc.
Phase 2
72
Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky, Mississippi
2024-12-20
Active, closed
A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT06727552Atopic Dermatitis
DrugBarzolvolimab
Celldex Therapeutics
Phase 2
131
Alabama, California, Florida, Georgia, Idaho, Illinois, Kentucky, Michigan
2024-12-18
Recruiting
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
NCT06753331Parkinson's Disease
Sumitomo Pharma America, Inc.
Phase 1/2
25
Kentucky, New York
2024-12-18
Active, closed
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
NCT06713239Coronary Artery Disease
Cleerly, Inc.
Not applicable
1,000
Alabama, California, Colorado, Florida, Illinois, Iowa, Kentucky, Louisiana
2024-12-18
Active, closed
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
NCT06712407IgA Nephropathy
DrugBudesonide
Calliditas Therapeutics AB
Phase 4
60
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky
2024-12-17
Recruiting
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
170
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Virginia
2024-12-16
Recruiting
Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects
NCT06730828Atrial Fibrillation, Postoperative
Helios Cardio Inc.
Phase 1/2
80
Kentucky
2024-12-16
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Alabama, California, Georgia, Indiana, Kentucky, Maryland, Michigan, Minnesota
2024-12-11
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan
2024-12-09
Recruiting
Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee
NCT06216756Osteochondral Defect
AlloSource
Not applicable
68
Arizona, California, Illinois, Kentucky
2024-12-01
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742Wet Age Related Macular Degeneration, wAMD
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2024-11-27
Active, closed
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT06498960Normal Pressure Hydrocephalus
CereVasc Inc
Not applicable
230
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2024-11-26
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Alabama, Arizona, California, Florida, Kentucky, New York, Pennsylvania, Virginia
2024-11-26
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky
2024-11-25
Active, closed
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038Pneumococcal Vaccines
DrugPrevnar 20
Vaxcyte, Inc.
Phase 2
900
Arkansas, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Nebraska
2024-11-25
Recruiting
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
NCT06619561Chronic Graft-Versus-Host Disease (cGVHD)
DrugVimseltinib
Deciphera Pharmaceuticals, LLC
Phase 2
48
California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2024-11-21
Active, closed
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
NCT06625177Vitiligo
DrugTEV-53408
Teva Branded Pharmaceutical Products R&D LLC
Phase 1
66
Arizona, Arkansas, California, Florida, Illinois, Kentucky, Michigan, Oregon
2024-11-11
Recruiting
PULSED AF Post-Approval Study
NCT06578104Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
580
Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan, Nebraska, New York
2024-11-04
Recruiting
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565Myasthenia Gravis
DrugEfgartigimod
argenx
Observational
680
California, Florida, Illinois, Iowa, Kansas, Kentucky, Massachusetts, Michigan
2024-11-04
Active, closed
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768Non-small Cell Lung Cancer, Lung Cancer
DrugsValemetostat·Valemetostat Tosylate·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 1/2
137
California, Florida, Kentucky, Minnesota, New York, Pennsylvania, Virginia
2024-10-30
Recruiting
Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)
NCT07670858Nodular Basal Cell Carcinoma
Feldan Therapeutics
Phase 1
48
Kentucky, New York
2024-10-30
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Arizona, California, District of Columbia, Florida, Illinois, Iowa, Kansas, Kentucky
2024-10-29
Recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT06481592Endometrial Cancer
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
60
Arizona, California, Florida, Georgia, Kentucky, Michigan, New York, Oklahoma
2024-10-29
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts
2024-10-24
Recruiting
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082Sickle Cell Disease
DrugCrizanlizumab
Novartis Pharmaceuticals
Phase 3
354
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2024-10-24
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide
Pfizer
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Maine
2024-10-21
Recruiting
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
NCT06382155Idiopathic Short Stature
DrugsHuman Growth Hormone·Vosoritide
BioMarin Pharmaceutical
Phase 2
100
California, District of Columbia, Florida, Georgia, Idaho, Iowa, Kentucky, Louisiana
2024-10-21
Active, closed
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844Non-small Cell Lung Cancer
DrugsRilvegostomig·Dato-DXd·Vinorelbine·Etoposide
AstraZeneca
Phase 3
25
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2024-10-15
Active, closed
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213Focal Onset Seizure
DrugCenobamate
SK Life Science, Inc.
Phase 4
49
Arizona, Arkansas, California, Connecticut, Florida, Idaho, Kentucky, Louisiana
2024-10-14
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
346
Arizona, California, Florida, Kentucky, Maryland, Massachusetts, Michigan, New Hampshire
2024-10-10
Recruiting
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
NCT06619990Ulcerative Colitis (UC)
Xencor, Inc.
Phase 1/2
270
Arizona, California, Florida, Kentucky, Mississippi, New York, North Carolina, Ohio
2024-10-10
Recruiting
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479Migraine
AbbVie
Phase 2
488
Alabama, California, Florida, Kentucky, New York, Rhode Island, South Carolina, Texas
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-10-04
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
California, Georgia, Illinois, Kentucky, Minnesota, Missouri, Nebraska, New York
2024-10-03
Active, closed
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
NCT06471543Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Ikaria Bioscience Pty Ltd
Phase 1/2
108
Florida, Kentucky, Minnesota, Texas, Utah
2024-09-30
Recruiting
Registry for Stage 2 Type 1 Diabetes
NCT06481904Type 1 Diabetes
DrugTzield
Sanofi
Observational
200
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-09-27
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
DrugsPetosemtamab·Pembrolizumab
Merus B.V.
Phase 3
699
Alabama, California, Delaware, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-09-25
Recruiting
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
NCT06462235Gram-negative Bacterial Infection
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Xeloda·Sacituzumab tirumotecan·Leucovorin
Merck Sharp & Dohme LLC
Phase 1/2
160
Arizona, California, Kentucky, Michigan, New York, Pennsylvania, Texas
2024-09-20
Active, closed
A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-World
NCT06728319Lung Nodules
Biodesix, Inc.
Observational
4,000
Florida, Kentucky, Massachusetts, Pennsylvania
2024-09-19
Active, closed
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895Multiple Myeloma
DrugsCilta-cel·Talquetamab
Janssen Research & Development, LLC
Phase 2
11
Iowa, Kentucky, Michigan, New York, Pennsylvania
2024-09-16
Active, closed
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Tectonic Therapeutic
Phase 2
191
Arizona, California, Colorado, Florida, Georgia, Idaho, Kentucky, Maryland
2024-09-04
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-09-03
Active, closed
LMN-201 for Prevention of C. Difficile Infection Recurrence
NCT05330182Clostridioides Difficile Infection
Lumen Bioscience, Inc.
Phase 2/3
375
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota, New York
2024-08-29
Active, closed
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228Asthma
DrugsICS/LABA·Dupilumab
Regeneron Pharmaceuticals
Phase 4
120
California, Colorado, Florida, Idaho, Illinois, Kansas, Kentucky, Maine
2024-08-26
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT06352359Advanced Solid Tumor
OncoC4, Inc.
Phase 1
72
California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah
2024-08-23
Active, closed
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
NCT06577090Obesity
Skye Bioscience, Inc.
Phase 2
136
Alabama, California, Connecticut, Georgia, Kentucky, Nebraska, Nevada, New Hampshire
2024-08-22
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
675
Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky
2024-08-19
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin
Genmab
Phase 3
379
California, Colorado, Georgia, Illinois, Indiana, Kansas, Kentucky, Maryland
2024-08-13
Recruiting
A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979Idiopathic Short Stature
BioMarin Pharmaceutical
Observational
300
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-08-08
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Arizona, California, Kentucky, Michigan, New York, Pennsylvania, Texas
2024-08-07
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
DrugsPumitamig·Topotecan·Etoposide·Paclitaxel
BioNTech SE
Phase 2
110
Alaska, California, Florida, Illinois, Indiana, Kentucky, Minnesota, Missouri
2024-08-05
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Maryland
2024-08-01
Recruiting
Vitaccess Real MG Registry
NCT06064461Myasthenia Gravis
Vitaccess Ltd
Observational
600
California, Illinois, Kentucky, New Jersey, South Carolina, Texas
2024-07-31
Active, closed
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
DrugsMIRV·Mirvetuximab Soravtansine
AbbVie
Phase 2
108
California, Kentucky, Maryland, Missouri, Nevada, New Jersey, New York, North Carolina
2024-07-29
Recruiting
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
NCT06560307Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
Enterra Medical, Inc.
Not applicable
50
Florida, Kentucky, Michigan, Missouri, Oregon, Washington
2024-07-25
Active, closed
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
NCT06524414Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 2
605
Arkansas, California, District of Columbia, Florida, Idaho, Iowa, Kansas, Kentucky
2024-07-25
Active, closed
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261Leukemia, Myeloid, Acute
DrugsCusatuzumab·Azacitidine·Venetoclax
OncoVerity, Inc.
Phase 2
140
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, New Jersey
2024-07-22
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
California, Colorado, Florida, Georgia, Kansas, Kentucky, Louisiana, Massachusetts
2024-07-19
Recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Generalized Myasthenia Gravis
DrugTelitacicept
Vor Biopharma
Phase 3
180
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts
2024-07-17
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
DrugsLumakras·Sotorasib·Bevacizumab-awwb·Panitumumab
Amgen
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Michigan
2024-07-17
Recruiting
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT05952024Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Rituximab
AstraZeneca
Phase 2
80
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Michigan, South Dakota
2024-07-16
Active, closed
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
NCT06096779Hepatocellular Carcinoma
DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab
Genentech, Inc.
Phase 2
30
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kentucky
2024-07-15
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
963
Alabama, California, Colorado, Florida, Idaho, Illinois, Indiana, Kentucky
2024-07-11
Recruiting
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
NCT06046495Non-Small Cell Lung Cancer
DrugAndamertinib
Avistone Biotechnology Co., Ltd.
Phase 1
81
California, Kentucky, Nebraska, New York, Tennessee, Washington
2024-07-08
Active, closed
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
NCT06325566Degenerative Disc Disease
Mesoblast, Ltd.
Phase 3
300
Arizona, California, Colorado, Florida, Georgia, Hawaii, Kansas, Kentucky
2024-07-03
Active, closed
Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia
NCT06449378Hernia, Hernia, Ventral, Hernia, Abdominal, Hernia Abdominal Wall
Medtronic - MITG
Not applicable
163
Illinois, Kentucky, North Carolina, Ohio, Virginia
2024-07-02
Recruiting
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
NCT06207032Cancer
Tempus AI
Observational
500
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-06-26
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
DrugTUB-040
Gilead Sciences
Phase 1/2
250
Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio
2024-06-12
Recruiting
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128Ulcerative Colitis
DrugsXeljanz·Vedolizumab·Tofacitinib
Takeda
Phase 4
60
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky
2024-06-12
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
DrugsBelrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 3
88
Florida, Hawaii, Kentucky, Nebraska, Tennessee, Texas, Washington
2024-06-10
Recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421Breast Cancer
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Recruiting
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Colorado, Connecticut, Florida, Kentucky, Missouri, Nevada, New Mexico, Oklahoma
2024-06-04
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel
Amgen
Phase 1
120
California, Colorado, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Missouri
2024-05-29
Active, closed
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 1
96
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2024-05-21
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan
Daiichi Sankyo
Phase 3
540
Arkansas, California, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2024-05-21
Active, closed
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712Cerebral Amyloid Angiopathy
DrugsAln-App·Mivelsiran
Alnylam Pharmaceuticals
Phase 2
210
California, Colorado, Connecticut, Florida, Illinois, Kentucky, Louisiana, Massachusetts
2024-05-17
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, Michigan, Missouri
2024-05-14
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2/3
390
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Kentucky, Louisiana
2024-05-13
Active, closed
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
NCT06422689Asthma
AstraZeneca
Phase 4
1,511
California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas
2024-05-10
Recruiting
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
NCT06218875AAA - Abdominal Aortic Aneurysm
W.L.Gore & Associates
Observational
2,000
Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana
2024-05-07
Active, closed
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT05973487Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
TScan Therapeutics, Inc.
Phase 1
840
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2024-05-06
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, North Dakota
2024-05-03
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2024-04-29
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
450
California, Colorado, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2024-04-26
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
1,200
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2024-04-14
Recruiting
Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.
NCT05796908Arthritis, Unstable Radial Head, Proximal Radioulnar Joint Instability, Decreased Motion at the Proximal Radioulnar Joint and/or the Radio-humeral Joint
Aptis Medical
Not applicable
84
Indiana, Kentucky, Massachusetts, Ohio, Pennsylvania, Wisconsin
2024-04-12
Recruiting
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06236438Non-Small Cell Lung Cancer
DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
840
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-04-10
Recruiting
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
NCT06316297Acne
DrugAcne mRNA vaccine
Sanofi Pasteur, a Sanofi Company
Phase 1/2
800
Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky
2024-04-05
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-04-03
Active, closed
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207Heart Failure, Systemic Inflammation
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
673
Alabama, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Maryland
2024-04-01
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
213
California, Florida, Georgia, Kentucky, Maryland, Nevada, Rhode Island, South Carolina
2024-03-29
Recruiting
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
DrugsFT819·Fludara·Bendamustine·Cytoxan
Fate Therapeutics
Phase 1
244
California, Florida, Kentucky, Minnesota, Nebraska, New York, North Carolina, Ohio
2024-03-28
Active, closed
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934Ulcerative Colitis
Gilead Sciences
Phase 2
228
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Louisiana
2024-03-27
Active, closed
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386Asthma
DrugMepolizumab
GlaxoSmithKline
Phase 4
336
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana, Maryland
2024-03-20
Recruiting
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
NCT04781140Attention-Deficit/Hyperactivity Disorder
DrugViloxazine
Supernus Pharmaceuticals, Inc.
Phase 4
286
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kentucky
2024-03-19
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
731
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2024-03-09
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461Crohn's Disease
DrugZasocitinib
Takeda
Phase 2
268
California, Florida, Georgia, Iowa, Kansas, Kentucky, Maryland, Missouri
2024-03-05
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-03-04
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey
2024-02-27
Active, closed
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159Myasthenia Gravis, Generalized
DrugClaseprubart
Dianthus Therapeutics
Phase 2
65
Arizona, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Massachusetts
2024-02-23
Recruiting
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
NCT06035120Emphysema, Pulmonary, Emphysema or COPD
Pulmonx Corporation
Not applicable
200
Arizona, Colorado, Connecticut, Florida, Illinois, Kentucky, Massachusetts, Michigan
2024-02-22
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
California, Connecticut, Florida, Kentucky, Louisiana, New Jersey, New York, North Carolina
2024-02-20
Recruiting
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059Idiopathic Pulmonary Fibrosis
DrugIfetroban
Cumberland Pharmaceuticals
Phase 2
128
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Michigan
2024-01-31
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
617
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2024-01-30
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
DrugsVVD-133214·Avastin·Keytruda·Bevacizumab
Vividion Therapeutics, Inc.
Phase 1
280
Arizona, California, Georgia, Illinois, Kentucky, Michigan, New Jersey, North Carolina
2024-01-25
Active, closed
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596Metastatic Urothelial Cancer
DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin
BicycleTx Limited
Phase 2
375
Colorado, Florida, Kansas, Kentucky, Nebraska, New York, South Carolina, Tennessee
2024-01-24
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
DrugsBelumosudil·Prednisolone·Prednisone
Sanofi
Phase 3
260
Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2024-01-23
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
774
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2024-01-17
Active, closed
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT06109272Hepatocellular Carcinoma
DrugsLivmoniplimab·Budigalimab·Tremelimumab·Atezolizumab
AbbVie
Phase 2/3
89
California, Illinois, Kansas, Kentucky, Michigan, Minnesota, Missouri, Texas
2024-01-11
Active, closed
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250Pulmonary Hypertension
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
230
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2024-01-10
By invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315Wheezing, Asthma
DrugDupilumab
Sanofi
Phase 3
90
Arizona, Florida, Illinois, Kentucky, Minnesota, New York, North Carolina, Ohio
2024-01-03
Recruiting
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
NCT06001827Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure
VenoStent
Not applicable
600
Arizona, California, Florida, Indiana, Kentucky, Massachusetts, Minnesota, Missouri
2024-01-03
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Louisiana
2023-12-31
Recruiting
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240Pulmonary Hypertension, Interstitial Lung Disease
Liquidia Technologies, Inc.
Observational
80
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kentucky, Massachusetts
2023-12-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
NCT06010329Non-small Cell Lung Cancer
DrugSutetinib Maleate
Teligene US
Phase 2
66
California, Florida, Georgia, Iowa, Kentucky, New York, Texas
2023-12-27
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
120
California, Colorado, Florida, Illinois, Indiana, Iowa, Kentucky, Maryland
2023-12-20
Recruiting
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511Multiple Myeloma
DrugLinvoseltamab
Regeneron Pharmaceuticals
Phase 1/2
149
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Active, closed
Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population
NCT07382076Activated Clotting Time
Abbott Point of Care
Observational
500
Arizona, California, District of Columbia, Kentucky, Maryland, Minnesota, Missouri, New York
2023-12-15
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Arizona, California, Colorado, Florida, Georgia, Kentucky, Maine, Massachusetts
2023-12-15
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
California, Kentucky, New York, Rhode Island, Texas
2023-12-13
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)
DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan
Regeneron Pharmaceuticals
Phase 3
904
Arizona, California, Florida, Indiana, Kentucky, Maryland, Massachusetts, Michigan
2023-12-13
Recruiting
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074Advanced Solid Malignancies
Georgiamune Inc
Phase 1/2
111
California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia
2023-12-12
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Abemaciclib·Ribociclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kentucky, Maine
2023-12-11
Active, closed
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
NCT06109441Ulcerative Colitis
DrugALTB-268
AltruBio Inc.
Phase 2
50
California, Colorado, Florida, Indiana, Kentucky, Louisiana, Mississippi, New York
2023-12-04
Recruiting
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
NCT06094010Influenza
DrugBaloxavir Marboxil
Hoffmann-La Roche
Phase 3
1,100
Alabama, Arkansas, Florida, Georgia, Idaho, Indiana, Kentucky, Louisiana
2023-11-22
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
DrugsLumakras·Sotorasib·Pembrolizumab
Amgen
Phase 3
750
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, New Mexico, New York
2023-11-16
Active, closed
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741Moderate to Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 2
396
Arkansas, California, Florida, Georgia, Indiana, Kentucky, Michigan, Nevada
2023-11-15
Active, closed
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364Follicular Lymphoma (FL)
DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan
Regeneron Pharmaceuticals
Phase 3
733
Florida, Indiana, Kansas, Kentucky, Michigan, Texas, Utah, Wisconsin
2023-11-14
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-11-07
Active, closed
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT06101134Melanoma
DrugsPhesgo·Relatlimab·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
Iowa, Kentucky, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2023-11-06
Active, closed
Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant
NCT06163404Nasal Septal Deviation, Nasal Airway Obstruction
Spirair, Inc
Not applicable
102
Alabama, California, Kentucky, Louisiana, New York, Pennsylvania, Washington
2023-11-01
Recruiting
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
NCT05561127Bowel; Stricture
GIE Medical
Phase 3
171
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2023-11-01
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
DrugsAbemaciclib·Fulvestrant
LeonaBio
Phase 3
600
Arizona, California, Florida, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2023-10-31
Recruiting
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
Obsidian Therapeutics, Inc.
Phase 1/2
254
California, Florida, Kentucky, New York, Ohio, Pennsylvania, Texas
2023-10-25
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
895
Arkansas, California, Colorado, Florida, Indiana, Iowa, Kentucky, Maryland
2023-10-24
Active, closed
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
NCT05995405Aneurysmal Subarachnoid Hemorrhage (aSAH)
DrugNimotop
Grace Therapeutics Inc.
Phase 3
100
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2023-10-20
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab
Genentech, Inc.
Phase 2
260
California, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Nebraska
2023-10-18
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Alabama, Arizona, California, Florida, Indiana, Kansas, Kentucky, Maryland
2023-10-13
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
684
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2023-10-12
Active, closed
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689Myelodysplastic Syndromes
DrugsReblozyl·Luspatercept
Bristol-Myers Squibb
Phase 3
106
California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey
2023-10-05
Recruiting
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
NCT06072131Peripheral T Cell Lymphoma
DrugsBelinostat·Pralatrexate·CHOP·Prednisone
Acrotech Biopharma Inc.
Phase 3
504
California, Colorado, Florida, Kentucky, Michigan, New Jersey, Texas
2023-10-04
Recruiting
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
NCT04929236Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
DrugPanzyga
Octapharma
Phase 3
30
Alabama, California, Kentucky, Pennsylvania, Texas, Virginia
2023-10-01
Recruiting
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
NCT05636618Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
Perspective Therapeutics
Phase 1/2
300
Florida, Illinois, Iowa, Kentucky, Maryland, Michigan, Minnesota, Missouri
2023-09-27
Active, closed
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
NCT05953337Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
ABK Biomedical
Not applicable
120
Arizona, California, Florida, Georgia, Illinois, Iowa, Kentucky, Louisiana
2023-09-21
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)
DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone
Regeneron Pharmaceuticals
Phase 3
410
California, Florida, Kentucky, New York, North Carolina, Oregon, Texas, Washington
2023-09-18
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
DrugsTiragolumab·Tecentriq·Avastin·Atezolizumab
Hoffmann-La Roche
Phase 3
687
Arkansas, California, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana
2023-09-14
Active, closed
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428Alopecia Areata
DrugBempikibart
Q32 Bio Inc.
Phase 2
75
Arizona, Arkansas, California, Connecticut, Florida, Indiana, Kentucky, Massachusetts
2023-09-12
Active, closed
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
NCT05664243Glioblastoma
In8bio Inc.
Phase 1/2
4
Alabama, Florida, Kentucky, Ohio
2023-09-08
Recruiting
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
NCT06014502Solid Tumor
ImmunoGenesis
Phase 1
105
Arizona, California, Florida, Kentucky, Louisiana, Missouri, Pennsylvania, Texas
2023-09-07
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
DrugSeladelpar
Gilead Sciences
Phase 3
402
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Kentucky
2023-09-07
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky, Maryland
2023-09-01
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Alabama, California, Florida, Georgia, Indiana, Kentucky, New Jersey, New York
2023-08-31
Active, closed
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination
NCT06007183Chikungunya Virus Infection
Bavarian Nordic
Phase 3
715
Alabama, Arizona, Florida, Illinois, Kansas, Kentucky, Missouri, Nevada
2023-08-30
Recruiting
US National OCS Heart Perfusion (OHP) Registry
NCT05915299Heart Transplant
TransMedics
Observational
100,000
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2023-08-25
Recruiting
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116Advanced Solid Tumors
DrugsBNT324·Itraconazole·Abiraterone·Enzalutamide
DualityBio Inc.
Phase 1/2
862
Arizona, California, Florida, Georgia, Kentucky, Michigan, Minnesota, Nevada
2023-08-17
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
DrugIza-bren
SystImmune Inc.
Phase 1
540
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa, Kentucky
2023-08-08
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
NCT05778188Hypoxic-Ischemic Encephalopathy
DrugRLS-0071
ReAlta Life Sciences, Inc.
Phase 2
70
Arkansas, California, Florida, Indiana, Kentucky, Massachusetts, Missouri, North Carolina
2023-07-27
Active, closed
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
NCT05680922Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
Legend Biotech USA Inc
Phase 1
41
Florida, Kentucky, Massachusetts, New York
2023-07-26
Active, closed
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451Chronic Spontaneous Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
100
California, Florida, Idaho, Illinois, Kentucky, Ohio, Oklahoma, Pennsylvania
2023-07-11
Recruiting
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
NCT05980455Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
Enterra Medical, Inc.
Not applicable
50
Kentucky, Minnesota
2023-07-10
Active, closed
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors
DrugsCalderasib·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
95
Illinois, Kentucky, New Jersey
2023-07-06
Active, closed
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Observational
760
Colorado, Florida, Georgia, Kentucky, Michigan, Minnesota, Mississippi, New Mexico
2023-06-28
Active, closed
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
NCT05520099Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
Elephas
Observational
416
Arkansas, California, Florida, Kentucky, Maryland, New Jersey, New York, North Carolina
2023-06-26
Active, closed
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
TScan Therapeutics, Inc.
Observational
1,150
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2023-06-26
Active, closed
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498Percutaneous Coronary Intervention
CathWorks Ltd.
Not applicable
1,924
California, Florida, Georgia, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2023-06-21
Active, closed
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
NCT05857930Recurrent Wheezing, Wheezing Lower Respiratory Illness
DrugBroncho-Vaxom
OM Pharma SA
Phase 2
296
Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Kentucky
2023-06-20
Recruiting
Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry
NCT05915078Otitis Media With Effusion, Acute Otitis Media, Otitis Media
Smith & Nephew, Inc.
Observational
200
Kentucky, New Jersey, New York, Utah
2023-06-15
Active, closed
NEUROMARK Registry Study
NCT05937308Chronic Rhinitis
Neurent Medical
Not applicable
150
Alabama, California, Florida, Kentucky, Texas, Utah, Virginia
2023-06-12
Active, closed
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer
DrugsOlaparib·Ipilimumab
Lantern Pharma Inc.
Phase 1/2
64
Arkansas, Indiana, Kentucky, Maryland, Pennsylvania, Texas, Utah
2023-06-09
Recruiting
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320Episodic Migraine
DrugEptinezumab
H. Lundbeck A/S
Phase 3
315
Connecticut, Florida, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2023-06-08
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
DrugsBupropion·Omeprazole·Alpelisib·Inavolisib
Hoffmann-La Roche
Phase 3
420
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan
2023-06-07
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island
2023-06-05
Recruiting
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
DrugNivolumab
Perspective Therapeutics
Phase 1/2
300
California, Florida, Iowa, Kentucky, Minnesota, Missouri, Nebraska, Pennsylvania
2023-06-01
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Alabama, Alaska, Arkansas, California, Illinois, Indiana, Iowa, Kentucky
2023-05-31
Active, closed
iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction
NCT05870488Sacroiliac Joint Dysfunction, Sacroiliac; Fusion, Sacroiliac Disorder, Sacroiliac Joint Pain
SI-BONE, Inc.
Phase 4
110
California, Indiana, Kansas, Kentucky, Maryland, Missouri, Nevada, Oklahoma
2023-05-23
Active, closed
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy
Impulse Dynamics
Not applicable
300
Arizona, California, Connecticut, Florida, Iowa, Kansas, Kentucky, Massachusetts
2023-05-17
Recruiting
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT05826535Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
DrugsRondecabtagene autoleucel·Fludarabine·Cyclophosphamide
Lyell Immunopharma, Inc.
Phase 1/2
270
California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky, Louisiana
2023-05-09
Recruiting
The Ailliance Post-Market Clinical Study
NCT05856370Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma
Medtronic Spinal and Biologics
Not applicable
1,000
Arizona, Arkansas, California, Indiana, Kentucky, Maryland, Michigan, Minnesota
2023-05-01
Recruiting
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102Asthma
DrugFF/UMEC/VI
GlaxoSmithKline
Phase 3
138
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-04-24
Active, closed
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
NCT05557591Advanced Non-Small Cell Lung Cancer
DrugsBNT116·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
51
California, Kentucky, New Mexico, New York, North Carolina, Texas, Virginia, Washington
2023-04-21
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
288
Alabama, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland
2023-04-21
Recruiting
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
NCT05685173B-cell Non-Hodgkins Lymphoma (B-NHL)
DrugOdronextamab
Regeneron Pharmaceuticals
Phase 1
107
California, Kentucky, Massachusetts, New Jersey, New York, Texas
2023-04-20
Active, closed
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
NCT05561374High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
Oblato, Inc.
Phase 1
16
California, Kentucky, North Carolina, Oklahoma
2023-04-17
Recruiting
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
NCT05758077Acute Kidney Injury
SeaStar Medical
Not applicable
339
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2023-04-17
Recruiting
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589Neurotrophic Keratopathy
ReGenTree, LLC
Phase 3
70
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2023-04-11
Active, closed
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
NCT05692180Asthma
DrugBenralizumab
AstraZeneca
Phase 3
94
California, Florida, Kentucky, Louisiana, Missouri, New Jersey, New York, Ohio
2023-04-05
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma
DrugsLifileucel·Pembrolizumab
Iovance Biotherapeutics, Inc.
Phase 3
670
Alabama, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2023-03-30
Active, closed
In-Office Clinical Study of the Solo+ TTD
NCT05741333Ear Infection, Otitis Media
AventaMed DAC
Not applicable
66
Alabama, California, Kentucky, Pennsylvania, South Carolina
2023-03-30
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 2
192
Arizona, Indiana, Kentucky, Missouri, Ohio, Oregon
2023-03-16
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Michigan
2023-03-16
Recruiting
Vivistim Registry for Paired VNS Therapy (GRASP)
NCT05301140Upper Extremity Problem
MicroTransponder Inc.
Observational
1,000
Florida, Illinois, Kansas, Kentucky, New Jersey, New York, Pennsylvania, Texas
2023-03-15
Recruiting
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
NCT05482893Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
DrugsNalirifox·Folfirinox·Trifluridine/Tipiracil·Abraxane
Phanes Therapeutics
Phase 1/2
350
California, Colorado, Iowa, Kentucky, Massachusetts, North Carolina, Pennsylvania, Texas
2023-03-15
Recruiting
A Study of ASP1002 in Adults for Treatment of Solid Tumors
NCT05719558Advanced Solid Tumors
DrugsRamucirumab·Trifluridine/Tipiracil·Fluorouracil·Leucovorin
Astellas Pharma Global Development, Inc.
Phase 1
798
Connecticut, Florida, Iowa, Kentucky, Michigan, Minnesota, New York, Ohio
2023-03-13
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
DrugsVepdegestrant·Fulvestrant
Pfizer
Phase 3
624
California, Connecticut, Florida, Illinois, Kentucky, Louisiana, Mississippi, Missouri
2023-03-03
Active, closed
Investigation of DEXA-C Anterior Cervical Interbody System
NCT05883436Degenerative Disc Disease
Aurora Spine and Pain
Not applicable
71
California, Kentucky, Louisiana, Oklahoma
2023-02-22
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
DrugsPegylated filgrastim·Pembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol
Merck Sharp & Dohme LLC
Phase 3
377
Arizona, Florida, Illinois, Indiana, Kentucky, Mississippi, Missouri
2023-02-14
Active, closed
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05607004Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
DrugsZoladex·Goserelin
Atossa Therapeutics, Inc.
Phase 2
87
Arizona, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2023-02-14
Recruiting
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418Relapsed/Refractory Multiple Myeloma
DrugsFludarabine·Cyclophosphamide
Caribou Biosciences, Inc.
Phase 1
50
Alabama, Colorado, Florida, Kentucky, New Jersey, New York, North Carolina, Ohio
2023-02-06
Active, closed
Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness
NCT05362370Cranioplasty, Craniofacial Abnormalities, Craniofacial Injuries
Stryker Craniomaxillofacial
Observational
99
Kentucky, New Jersey, New York, Pennsylvania, South Carolina
2023-02-01
Active, closed
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
DrugDexpramipexole Dihydrochloride
Areteia Therapeutics
Phase 3
600
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2023-01-30
Active, closed
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
DrugsAlcestobart·Fluoropyrimidine·Bevacizumab biosimilar·Tislelizumab
BeiGene
Phase 1/2
113
Alaska, Arizona, California, Florida, Indiana, Kentucky, Louisiana, Missouri
2023-01-29
Active, closed
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
NCT05642780Solid Tumor
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Klus Pharma Inc.
Phase 2
240
Indiana, Kentucky, Maryland, Minnesota, New York, Texas, Virginia
2023-01-17
Active, closed
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
NCT05438420Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
DrugsAdrixetinib·Keytruda·Pembrolizumab
Qurient Co., Ltd.
Phase 1/2
120
California, Kentucky
2023-01-12
Active, closed
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013Crohn Disease, Colitis, Ulcerative
DrugDuvakitug
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
247
California, Florida, Illinois, Indiana, Kansas, Kentucky, Missouri, Nevada
2023-01-11
By invitation
Tornier HRS (Humeral Reconstruction System) Study (REVIVE)
NCT05500066Rheumatoid Arthritis, Osteoarthritis Shoulder, Fractures Humerus, Avascular Necrosis
Stryker Trauma and Extremities
Observational
110
Colorado, Florida, Kentucky
2023-01-11
Recruiting
Alleviant ALLAY-HF Study
NCT05685303Heart Failure
Alleviant Medical, Inc.
Not applicable
700
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2023-01-10
Active, closed
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT05322590Metastatic Colorectal Carcinoma, Neuropathy
Bexion Pharmaceuticals, Inc.
Phase 1/2
195
Alabama, California, Florida, Iowa, Kentucky, Louisiana, New York, Ohio
2023-01-09
Recruiting
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis
DrugDapansutrile
Olatec Therapeutics, Inc.
Phase 2/3
300
Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan
2023-01-06
By invitation
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
NCT05768386Hemophilia A
BioMarin Pharmaceutical
Observational
172
California, Colorado, Florida, Kentucky, Michigan, Missouri, Ohio, Pennsylvania
2023-01-01
Active, closed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642Chronic Obstructive Pulmonary Disease (COPD)
DrugAstegolimab
Hoffmann-La Roche
Phase 3
1,290
Alabama, Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2022-12-29
By invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536Breast Cancer
DrugsTOL2506·Tamoxifen·Exemestane·Anastrozole
Tolmar Inc.
Phase 3
250
California, Florida, Kentucky, Maryland, New York, North Carolina, Pennsylvania, Tennessee
2022-12-28
Recruiting
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
Orano Med Theranostics, SAS
Phase 1
48
Illinois, Iowa, Kentucky, Maryland, Nebraska, Pennsylvania
2022-12-22
Active, closed
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsGotistobart·Keytruda·Pembrolizumab
OncoC4, Inc.
Phase 2
58
Arizona, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana, Minnesota
2022-12-22
Recruiting
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297Advanced Melanoma
DrugTebentafusp
Immunocore Ltd
Phase 3
540
Arizona, Florida, Georgia, Kansas, Kentucky, Massachusetts, Minnesota, Missouri
2022-12-19
Active, closed
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
DrugsCHS-114·Toripalimab
Coherus Oncology, Inc.
Phase 1
87
California, Georgia, Kentucky, Maryland, Michigan, Missouri, Ohio, Tennessee
2022-12-15
Active, closed
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351Severe Hypertriglyceridemia
DrugOlezarsen
Ionis Pharmaceuticals, Inc.
Phase 3
885
California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana
2022-12-13
Active, closed
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
DrugIP-001
Immunophotonics, Inc.
Phase 1/2
42
Florida, Kentucky, Oklahoma
2022-11-29
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2022-11-21
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Arizona, California, Florida, Illinois, Kentucky, Maryland, Michigan, Pennsylvania
2022-11-21
Active, closed
Embody Post-Market Clinical Follow-Up Study
NCT05735119Tendon Injuries- Subscapularis
Zimmer Biomet
Observational
100
California, Florida, Indiana, Kentucky
2022-11-09
Recruiting
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
NCT05452941Pneumonia
Pfizer
Observational
12,500
California, Connecticut, District of Columbia, Georgia, Kentucky, Louisiana, Maryland, Massachusetts
2022-10-27
Recruiting
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141Clear Cell Renal Cell Carcinoma, Solid Tumors
DrugsCasdatifan·Zimberelimab·Cabozantinib·Ipilimumab
Arcus Biosciences, Inc.
Phase 1
362
Alabama, California, Florida, Georgia, Kentucky, Louisiana, Maryland, Massachusetts
2022-10-26
Active, closed
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
NCT05481151Polycythemia Vera
DrugBesremi
PharmaEssentia
Phase 3
111
Florida, Indiana, Kansas, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2022-10-26
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
DrugsTucatinib·Erbitux·Herceptin·Avastin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Minnesota
2022-10-24
Active, closed
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
NCT05595460SCLC,Extensive Stage
DrugsRYZ101·Etoposide·Atezolizumab·Carboplatin
RayzeBio, Inc.
Phase 1
21
California, Florida, Iowa, Kentucky, Michigan, Minnesota, Missouri, Nebraska
2022-10-10
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NCT05443126NSCLC
DrugPemetrexed
Ellipses Pharma
Phase 1/2
265
California, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan, New York
2022-09-30
Recruiting
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NCT05283226Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
NATCO Pharma Ltd.
Phase 2
21
California, Florida, Kentucky, Maryland, Missouri, New Hampshire, Pennsylvania, Wisconsin
2022-09-30
Active, closed
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
NCT05482971Essential Thrombocythemia
DrugBesremi
PharmaEssentia
Phase 2
91
Alabama, California, Connecticut, District of Columbia, Georgia, Indiana, Kentucky, Louisiana
2022-09-29
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Alabama, Connecticut, Florida, Kansas, Kentucky, Missouri, New York, Oklahoma
2022-09-27
Rows per page Showing 1–500 of 771
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/kentucky

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 771 of those studies with a site in Kentucky.

How many clinical trials are recruiting in Kentucky?

371 of the 771 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 10 have not yet opened recruitment, 377 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kentucky), 771 studies
PhaseStudiesRecruitingShare
Phase 326411334.2%
Phase 21648021.3%
Not applicable873811.3%
Observational854011%
Phase 1/276489.9%
Phase 158387.5%
Phase 41962.5%
Phase 2/31882.3%

Most active sponsors

Lead sponsors with the most studies (Kentucky)
Lead sponsorStudiesRecruiting
AstraZeneca4215
Merck Sharp & Dohme LLC3819
Eli Lilly and Company2212
Janssen Research & Development, LLC206
AbbVie1910
Regeneron Pharmaceuticals1611
Hoffmann-La Roche156
Pfizer148
Novartis Pharmaceuticals125
Sanofi126
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.